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INTRODUCTION
Approximately 85% of newly diagnosed Wilms tumor
patients are now cured using multimodal therapies, but
patients who relapse or who have refractory disease have a
poor prognosis. According to the findings of National Wilms
Tumor Studies (NWTS) II and III, the three-year overall
survival rate after relapse was only 30±3% (1). Pinkerton
et al. (2) reported that even a low risk group with focal relapse
had a survival rate lower than 50%, thus once relapsed the
prognosis is very poor. Poor prognostic factors, as identified
by previous NWTS, are a stage >II, an unfavorable histology,
early relapse at <12 months after initial diagnosis, previous
combinatorial treatment with three agents, or abdominal
relapse at the site of previous abdominal radiation therapy
(1). New agents, except actinomycin, vincristine, and dox-
orubicin, have been investigated. Ifosfamide, etoposide, and
carboplatin have been demonstrated to be active as single
agents by several phase II clinical trials (3-5). The response
rates to these drugs as single agents in children with relapsed
Wilms tumor were 50%, 42%, and 40-53%, respectively.
The combined use of these agents has been examined to iden-
tify possible synergistic anti-tumor effects for the treatment
of relapsed pediatric solid tumors. The combination of car-
boplatin and etoposide resulted in an overall response rate of
43-83% (6), and ifosfamide and etoposide resulted in 55%
(7) when used in children with a variety of pediatric solid
tumors. However, none of these approaches improved long-
term survival to above 30%. Consequently dose-response strate-
gies were investigated. High dose chemotherapy (HDC) with
stem cell rescue (SCR) has been tried with the aim of achiev-
ing a long-term disease free state (8-11). Although a small
numbers of patients (i.e., <25 patients) in each study under-
went HDC with SCR, the 4 yr event-free survival rates were
reported in 40-60%. However, relapsed patients were a small
heterogeneous group, and it has not been established whether
this approach is superior to maintenance chemotherapy with
newer agents in high-risk patients. 
Here, we report on our experience of treating patients with
relapsed Wilms tumor over a period of 20 yr, focusing on the
survivals according to the treatment period.
MATERIALS AND METHODS
From January 1983 to December 2004, 98 patients were
diagnosed with Wilms tumor at the Seoul National Universi-
ty Children’s Hospital. We divided these patients into two
groups according to the date of relapse. The first group includ-
ed patients who relapsed between 1983 and 1993 (the “early”
group), and the second group included patients who relapsed
between 1994 and 2004 (the “late” group). Among the 98
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Improved Survival in Patients with Recurrent Wilms Tumor: 
the Experience of the Seoul National University Children’ s Hospital
The survival in cases with relapsed Wilms tumor is dismal. Recently, however the
introduction of new therapeutic agents and experimental strategies has improved
the survival. We analysed the survival of patients with relapsed Wilms tumor accord-
ing to the treatment period. During the early period 1983-1993, patients who had
received two drugs were treated with doxorubicin and the others were treated with
cisplatin and etoposide, whereas during the late period 1994-2004, patients were
treated with combinations of cyclophosphamide/etoposide and carboplatin/etopo-
side. During the early period, 8 of 57 experienced relapse, and 8 of 41 relapsed dur-
ing the late period. Only 2 patients treated during the early period survived in com-
plete response (CR), whereas during the late period, 5 patients remained alive in
CR, and 3 of those received high-dose chemotherapy (HDC) with autologous periph-
eral stem cell rescue (SCR). The estimated 5 yr event-free survival rate was 37.5%
in the entire study group, 50% for patients in the late period, and 25% for patients
in the early period (p=0.38). The survival in patients with relapsed Wilms tumor dra-
matically improved during the late period and HDC with SCR was one of the effec-
tive salvage strategies.
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patients, 16 (16.3%) experienced relapse. In the early group
8 of 57 experienced relapse and in the late group 8 of 41
relapsed. 
Nephrectomy was generally performed before chemothera-
py. The tumor stage and histological type were assigned accord-
ing to the guidelines of the NWTS (12). Patients with stage
I were treated with Reg. EE (25 weeks) or EE4A (18 weeks),
stage II with K (65 weeks) or K4 (60 weeks), and stage III
and IV with DD (65 weeks) or DD4A (24 weeks). Radiation
therapy was administered to patients with stage III and IV,
or an unfavorable histology. Computed tomography (CT)
scans of chest and abdomen were checked every three months.
At the time of relapse, any evidence of disease in the lungs
was assessed by chest radiography and CT scan; in the abdo-
men by CT scan and ultrasonographic examination; in the
skeleton by roentgenogram and bone scan; and in the bone
marrow by bone marrow aspiration and biopsy. The same
imaging strategy was used to assess the response to second-
line treatment.
In the early group (1983-1993), doxorubicin (D) was added
in cases who had received two drugs (actinomycin and vin-
cristine), and the others were treated with cisplatin and etopo-
side at the time of relapse. In the late group (1994-2004),
patients were treated with combinations of cyclophosphamide
(440 mg/m2/day, 5 days)/etoposide (100 mg/m2/day, 5 days)
and carboplatin (500 mg/m2/day, 2 days)/etoposide (100 mg/
m2/day, 3 days) (13). There was no uniform approach to surgery
or radiation therapy at the time of relapse. Response after two
cycles of second-line chemotherapy was defined as follows:
no response (NR) as a less than 50% reduction in tumor size
or disease progression; partial response (PR) as a ≥50% reduc-
tion in the sum of the perpendiculars of all measurable lesions;
and complete response (CR) as the disappearance of all mea-
surable disease.
Patients with chemosensitive tumors in CR or PR after
second-line treatment underwent HDC and SCR. Hemato-
poietic stem cells were collected through a double-lumen
central venous line after chemotherapy with cyclophosphamide
(1,000 mg/m2/day, 3 days) and etoposide (150 mg/m2/day,
3 days). Stem cells were mobilized using recombinant human
granulocyte-colony stimulating factor (rHG-CSF) at 10  g/
kg/day after day 7 of chemotherapy. The collection was per-
formed on the day when the peripheral white blood count
was >1,000/ L with the presence of monocytes by a COBE
spectra (Gambro BCT, Inc., Lakewood, CO, U.S.A.). Cells
were then transported to the stem cell laboratory for count-
ing and culture; they were stored at -196℃ until reinfusion
on day 0. The conditioning regimen consisted of melphalan
(140 mg/m2/day on day -7, 70 mg/m2/day on day -6), etopo-
side (200 mg/m2/day, on day -8 through -5) and carboplatin
(400 mg/m2/day, on day -8 through -5). Cells were infused
on day 0 after hydration and urine alkalinization had been
achieved. rHG-CSF was given subcutaneously starting on
day +1 of cell infusion at a dose of 10  g/kg/day and was con-
tinued until the absolute neutrophil count was >1,000/ L
for 2 consecutive days. Irradiated blood products and antimi-
crobial therapy were instituted when indicated. For the pro-
phylaxis of hepatic veno-occlusive disease low molecular weight
heparin (Nadroparin
� and lipo-prostaglandin E1 (Eglandin
�)
were given from day -8 for about 1 month.
Statistical analysis
The duration of overall survival was defined as the period
between the date of first relapse and either the date of death
(from any cause) or the date of the patient’s most recent fol-
low-up. The duration of event-free survival was defined as
the period between the date of first relapse and either the date
of disease progression or relapse, the date of the most recent
follow-up, or the date of death. Probabilities of overall sur-
vival and event-free survival were estimated using the Kaplan-
Meier method. The log rank test was used to compare pro-
portions, and the SPSS 12.0 software was used for the statis-
tical analysis.
RESULTS
The patient characteristics are listed in Table 1. Eleven boys
and five girls were enrolled in our study, and the median age
at diagnosis was 29 months (range, 3-119 months). Two
patients had stage I, 10 had stage II, 1 had stage III, and 3
had stage IV at the time of diagnosis. The median time from
diagnosis to relapse was 11 months (range 2 months-89 mon-
ths). The sites of relapse were lung (n=8), abdomen (n=5),
lung and abdomen (n=1), bone and liver (n=1), and abdomen,
lung, and bone marrow (n=1).
During the early period (1983-1993), two patients remained
alive in CR, 3 had a second relapse, 2 had progressive disease,
and 1 was lost to follow-up immediately after relapse. After
1994, 8 patients relapsed. One patient with a cleft lip and
palate was lost to follow-up immediately after relapse, and
another patient had progressive disease and died within 1
month from relapse. Two patients had a second relapse after
6 and 8 months of second-line treatment, respectively. One
patient with second relapse in the lung was cured by chemo-
therapy, pulmonary radiation, and tumorectomy. Another
patient with relapse in the abdomen during the initial che-
motherapy (Reg. K) received Reg. DD4 chemotherapy and
abdominal radiation. However, pleural effusion developed
and the disease progressed despite additional chemotherapy
(according to CCG 4921), and this patient died 15 months
after relapse. Four patients achieved continuous CR with sec-
ond-line treatment and 3 of these received HDC with autolo-
gous peripheral SCR. The numbers of infused mononuclear
cell were 20.9×108/kg, 5.64×108/kg, and 10.35×108/kg
and those of CD34+ cells were 9.16×106/kg, 7.7×106/kg,
and 17×106/kg, respectively. All three patients had grade438 E.S. Park, H.J. Kang, H.Y. Shin, et al.
IV neutropenia and thrombocytopenia, and needed total par-
enteral nutrition. Hepatic veno-occlusive disease developed
in one patient and lipo-prostaglandin E1 dose incrementation
(1.7  g/kg/day) and low dose dopamine were needed to con-
trol the disease. All three patients achieved complete recov-
ery of hematopoiesis and had no permanent sequelae. One
patient with disease relapse in abdomen, lung, and bone mar-
row achieved CR during the second-line treatment and then
received maintenance chemotherapy and radiation therapy
at the site of relapse. He has remained alive without evidence
of disease for 20 months. The patient outcomes are summa-
rized in Fig. 1.
Twelve patients out of 16 (75%) had at least one poor pro-
gnostic factor. The numbers of risk factors in individual pati-
ents are listed in Table 1. The estimated 5-yr event-free sur-
vival rates were 37.5% in the entire study group, 50% in
patients in the late group, and 25% in patients in the early
group (p=0.38). The overall survival rate in the late group
and early group were 62.5% and 25%, respectively (p=0.28)
(Fig. 2).
DISCUSSION
Suh et al. (14) have reported on the epidemiology and clin-
ical outcomes of childhood Wilms tumor at 26 major Korean
centers over the past 10 yr. The relapse rate was found to be
12% (29/246), and the estimated survival for relapsed Wilms
tumor was 40.9%. Choi et al. (15) studied the prognostic
factors and the efficacies of chemotherapeutic agents after
relapse. They used a combination of cisplatin, etoposide, cy-
clophosphamide, and ifosfamide, and concluded that no spe-
No.
Sex/Age
(yr)
Initial
stage
Previous
chemo-
therapy
Chemotherapy
after relapse
Interval 
from
Dx to
relapse (mo)
Site 
of 
relapse
RT after
relapse
Prev. 
three 
drug 
therapy
No. of
*risk 
factor
Survival
after 
relapse
(mo)
Event
after 
relapse
(mo)
Out-
come
Histology
1 M/3 II F K DD 89 A 0 176+ 176 CCR
2 M/1 I F EE DD 22 A 0 190+ 190 CCR
3 F/1 II F K4 C+E 8 Lg 1 12 12 NR
4 M/9 I F EE4 DD4+E 11 A 2 19 10 RL2
5 F/10 II F ND 4921 68 Lg 0 1 1 NR
6 M/2 III F DD4 C+E 23 Lg + 2 30 6 RL2
7 F/1 II F K4 DD4 18 Lg 0 12 1 RL2
8 M/6 II F K4 ND 2 Lg 1 1 1 FL
9 F/11 IV F DD4, C+E ND 11 A, Lg + + 5 2 2 NR
10 M/7 II F K4 DD4, 4921 8 Lg 1 130+ 8 RL2
11 M/2 II F K DD4, 4921 3 A 1 15 6 RL2
12 M/3 II U K4 4921, PBSCT 3 Lg 2 76+ 76 CCR
13 F/2 II U DD4 4921, PBSCT 6 Lg + + 3 53+ 53 CCR
14 M/1 IV F DD4 ND 20 Bo, Lv + + 2 3 3 FL
15 M/2 II F EE4 4921, PBSCT 9 A 1 31+ 31 CCR
16 M/1 IV F DD4 4921 11 A, Lg, BM + + 5 20+ 20 CCR
Table 1. Clinical and laboratory characteristics in patients with relapsed Wilms tumor 
*Risk factors included; an initial stage over 2, unfavorable histology, initial remission lasting <12 months, relapse at the irradiated site, abdomen or lung,
and prior three drug chemotherapy.
RT, radiation therapy; RL, relapse; F, favorable; U, unfavorable; C, cisplatin; E, etoposide; 4921, CCG 4921; PBSCT, peripheral blood stem cell trans-
plantation; ND, not done, A, abdomen; Lg, lung; Lv, liver; Bo, bone; BM, bone marrow; +, indicate patients alive; CCR, continuous complete response;
NR, no response; RL2, second relapse; FL, follow up loss.
Fig. 1. Outcome according to the date of relapse. Actinomycin, vin-
cristine and doxorubicin were used pre-1994, and subsequently
carboplatin, etoposide and cyclophosphamide were used. From
1994, 4 patients were given high-dose chemotherapy and periph-
eral stem cell transplantation. All remain alive without event. Two
pre-1994 patients and 5 post-1993 patients remain alive, respec-
tively. 
RL, relapse; CR, complete response; CCR, continuous complete
response; RL2, second relapse; NR, no response; AL, alive; Exp,
expired. 
16
1983-
1993
1994-
2004
RL 8
CR 5
RL2 3
AL in CR- -0
Exp - - - - - 3
AL in CR- -2
Exp - - - - - 2
CCR 2
NR 2
FL 1 Exp - - - - - 1
RL 8
CR 6
RL2 2
AL in CR- -1
Exp - - - - - 1
AL in CR- -4
Exp - - - - - 1
CCR 4
NR 1
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cific chemotherapeutic agents significantly improved the sur-
vival of relapsed patients. Our data at the Seoul National Uni-
versity Children’s Hospital indicate that progress has been
made in the treatment of patients with relapsed Wilms tumor.
Patients treated for recurrence during or since 1994 showed
significantly better event-free and overall survivals than those
treated earlier. This improvement in survival might be attri-
buted to higher salvage rate after relapse. In the late group 4
of 6 remained alive in CCR whereas 2 of 5 in the early group.
Moreover, 2 patients who survived in the early cohort had
no risk factors, while all patients had more than one risk fac-
tor in the late cohort. All of three patients who experienced
a second relapse (RL2) in the early cohort were lost to follow-
up, but one patient in the late cohort was salvaged with CCG
4921 chemotherapy, local radiation, and tumorectomy. Pati-
ents who relapsed in the late cohort received agents that were
not included in their previous treatment regimens. These
patients received a combination of cyclophosphamide, etopo-
side, and carboplatin, all of which were known to have a sig-
nificant activity against Wilms tumor. Six of them achieved
CR. Although these agents could achieve CR or PR (CR+PR
rate; 60-80%) their long-term survival estimates were report-
ed to be <40% (16). Tannous et al. (13) reported the results
of an intergroup CCG and POG trial of a retrieval study in
children with a relapsed Wilms tumor. CR (42%) and PR
(36%) were achieved after two cycles of induction chemother-
apy. Patients in CR were treated with cycles of maintenance
chemotherapy. The reported event-free and overall survivals
of these patients were 59% and 64%, respectively. Abu-Ghosh
et al. (17) reported similar results for ICE chemotherapy. Ifos-
famide was administered to patients with high-risk Wilms
tumor at a dose of 1,800 mg/m2/day for 5 days, carboplatin
400 mg/m2/day for 2 days, and etoposide 100 mg/m2/day for
5 days. Patients received a median of four cycles of ICE che-
motherapy (range 1-12), and the response to ICE was evalu-
ated after two or more cycles. In 11 patients enrolled the res-
ponse rate was 82% (CR+PR, 27%+55%), and their long-
term 3-yr EFS was 63.6%. The post ICE consolidative app-
roach was individualized and included; no more treatment,
chemotherapy only, chemotherapy and radiation therapy, and
surgery only. Two of 11 patients in PR received SCR.
Many groups have investigated the dose-dependent effica-
cies of chemotherapies in terms of prolonging the disease-
free period. Our data included three patients who underwent
HDC and SCR, and all of them have remained alive without
any evidence of disease for 76, 53, and 31 months after relapse,
respectively. Moreover, two of the three had an unfavorable
histology at diagnosis and relapsed within 6 months. Pein
et al. (9) of the French Society of Pediatric Oncology initiat-
ed a prospective study of HDC and SCR in 29 children with
high-risk factors. The conditioning regimen used consisted
of a combination of melphalan, etoposide, and carboplatin.
The estimated 3 yr overall and disease-free survivals were
60% and 50%, respectively. However, late relapse has been
documented at 26, 30, 47, and 53 months post HD chemo-
therapy. Kremens et al. (10) of the German Society of Pedi-
atric Oncology and Hematology attempted the same strategy
in 23 patients with high-risk criteria. The same conditioning
regimen including melphalan, etoposide, and carboplatin
was used in 20 patients. Among 23 patients relapse or pro-
gression occurred in 12 patients, and the overall and disease-
free survivals were 60.9% and 48.2%, respectively, after a
median follow-up of 58 months (range, 37-116 months). Toxic
side effects mainly involved hematopoiesis and gastrointesti-
nal mucosa, and the morbidity was considerable, but no treat-
ment-related mortality occurred. All patients experienced
grade IV neutropenia and fever but the rate of culture-proven
infection was low. Grade III or IV gastrointestinal mucositis,
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Fig. 2. Overall survival (OS, A) and event-free survival (EFS, B) as determined using the Kaplan-Meier method. Estimates of OS were 62.5%
and 25% (p=0.38), and EFS were 50% and 25% (p=0.28), respectively. The above figures show a markedly improved survival rate post-
1993, albeit without a statistical significance. 
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nausea, and vomiting were frequently observed in over half
of the patients, who needed parenteral nutritional support.
Other toxicities involving liver, lung, and kidney were rever-
sible. Campbell et al. (11) recently reported on the efficacy
of a thiotepa and cyclophosphamide-based conditioning regi-
men. Thirteen children with relapsed Wilms tumor were
enrolled, and 4 of those underwent two cycles of HD chemo-
therapy and SCR. After a median follow-up of 25 months,
the estimated 4-yr OS and EFS rates were 73% and 60%,
respectively. No increase in toxicity was observed in patients
who underwent two versus one cycle of HDC and SCR. Thus
for patients unable to achieve CR on standard-dose chemother-
apy, tandem cycles of HDC with SCR may confer a survival
advantage.
It remains to be determined whether intensive maintenance
chemotherapy versus HDC with SCR is required to extend
disease free survival in high-risk patients. However, HDC
with SCR should be considered for patients with PR after
second-line chemotherapy. Furthermore, the search for new
active agents should continue to treat those with measurable
disease after second line chemotherapy.
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